Sign In
Buy EYEG
$35.20
-0.0772 (-0.219%)
At Close: Jun 03, 2026
EyeGate Pharma Announces First Patient Dosed for PP-001 in a Phase 2 Proof-of-Concept Ocular Surface Inflammation Study
06:55am, Monday, 14'th Jun 2021
- Proof-of-concept study conducted in Austria- -Topline data expected in Q4 2021-
EyeGate Pharma Reports First Quarter 2021 Financial Results and Provides Business Update
04:15pm, Wednesday, 12'th May 2021
- PP-001: proof-of-concept study in Austria for dry eye patients expected to initiate in Q3:21; U.S. IND submission planned in Q4:21-
EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors
06:55am, Thursday, 01'st Apr 2021
WALTHAM, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflam
EyeGate Pharma Reports Full Year 2020 Financial Results and Provides Business Update
04:15pm, Thursday, 25'th Mar 2021
WALTHAM, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products
EyeGate Pharmaceuticals Announces Management Transition In Support of Strategic Transformation
06:55am, Monday, 01'st Feb 2021
- Franz Obermayr, Ph.D. Appointed as Acting Chief Executive Officer, Transitioning From EVP Clinical Development -
